CardioCel® 用于先天性心脏缺陷修复:全国逾1000例植入结果
该回顾性研究纳入澳大利亚3个先天性心脏病外科中心的752例18岁以下患者,共植入1184枚CardioCel补片,中位随访2.1年,1年、3年、5年免于CardioCel相关再干预概率分别为93%、91%、88%;多变量分析显示主动脉瓣修复及新生儿(尤其肺动脉扩大)再干预风险较高。
要点
- 752例患儿植入1184枚CardioCel补片,中位随访2.1年,5年免于相关再干预概率88%。
- 主动脉瓣修复再干预风险较高(HR=7.15,P=0.008)。
- 新生儿再干预风险较高(HR=6.71,P=0.0007),肺动脉扩大时尤甚(HR=14.38,P=0.029)。
核心结论
- CardioCel可用于多种先天性心脏缺陷的修复;在本研究中,新生儿用其扩大肺动脉及用于主动脉瓣修复时再干预率高于其他部位。
研究设计与样本
- 回顾性研究,数据来自澳大利亚3个先天性心脏病外科中心的数据库和医院记录,共752例18岁以下患者植入1184枚CardioCel补片。
- 采用Kaplan-Meier曲线和log-rank检验分析患者年龄、性别、补片类型与植入部位之间的关联;多变量Cox回归在校正年龄组、性别和补片类型后检验特定植入部位是否与再干预风险相关。
主要发现
- 植入时中位年龄12个月(IQR 3.6-84),中位随访2.1年(IQR 0.6-4.6)。
- 免于CardioCel相关再干预的概率:1年93%(95%CI 91-95),3年91%(95%CI 88-93),5年88%(95%CI 85-91)。
- 多变量回归分析中,与其他部位相比,主动脉瓣修复再干预发生率更高(HR=7.15,P=0.008)。
- 与其他年龄组相比,新生儿再干预概率更高(HR=6.71,P=0.0007),尤其是用于肺动脉扩大时(HR=14.38,P=0.029)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the mid-term performance of CardioCel for the repair of congenital heart defects. METHODS: Data were retrospectively collected from databases and hospital records in 3 congenital cardiac surgery centres in Australia. Kaplan-Meier curves and log-rank tests were used to test for associations between patient age, gender, patch type and site of implantation. Multivariable Cox regression was used to test whether any specific implantation site was associated with reintervention risk, after adjusting for age group, gender and patch type. RESULTS: A total of 1184 CardioCel patches were implanted in 752 patients under the age of 18 years. Median age at implant was 12 months [interquartile range (IQR) 3.6-84]. Median follow-up was 2.1 years (IQR 0.6-4.6). Probability of freedom from CardioCel-related reintervention was 93% [95% confidence interval (CI) 91-95] at 1 year, 91% (95% CI 88-93) at 3 years and 88% (95% CI 85-91) at 5 years, respectively. On multivariable regression analysis, aortic valve repair had a higher incidence of reintervention [hazard ratio (HR) = 7.15, P = 0.008] compared to other sites. The probability of reintervention was higher in neonates (HR = 6.71, P = 0.0007), especially when used for augmentation of the pulmonary arteries (HR = 14.38, P = 0.029), as compared to other age groups. CONCLUSIONS: CardioCel can be used for the repair of a variety of congenital heart defects. In our study, in patients receiving a CardioCel implant, reinterventions were higher when CardioCel was used to augment the pulmonary arteries in neonates and for aortic valve repair as compared to other sites.
引用
- Patukale AA, Marathe SP, Betts KS, et al. CardioCel® for repair of congenital heart defects: nationwide results of over 1000 implants. Eur J Cardiothorac Surg. 2023. PMID: 37846036. doi:10.1093/ejcts/ezad343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。